Letrozol Stada

Letrozole, the active ingredient in Letrozol Stada, is an aromatase inhibitor presented as an oral tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Stada is an aromatase inhibitor indicated for conditions driven by estrogen production.

- Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen synthesis to inhibit tumor growth. - Adjuvant therapy for early‑stage breast cancer: helps prevent disease recurrence after surgery. - Metastatic breast cancer: provides disease control when used with other systemic agents.

Letrozol Stada may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: arthralgia or myalgia. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fracture: increased risk due to lowered estrogen. - Pulmonary embolism: sudden shortness of breath, chest pain. - Allergic reaction (anaphylaxis): hives, swelling, airway compromise. - QT interval prolongation: cardiac rhythm disturbance.

Before initiating Letrozol Stada, clinicians should consider several safety measures.

- Assess bone health: monitor for osteoporosis and consider calcium/vitamin D supplementation. - Monitor liver function: check transaminases periodically. - Evaluate cardiovascular risk: watch for signs of thromboembolic events. - Avoid use in premenopausal women: drug is ineffective without postmenopausal estrogen levels. - Pregnancy warning: contraindicated in pregnancy; effective contraception required. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Letrozol Stada can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent tamoxifen: antagonistic effect on estrogen blockade. - Strong CYP2C19 inhibitors (e.g., fluconazole): may raise letrozole plasma levels. - Hormone replacement therapy: diminishes letrozole’s therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - CYP3A4 inducers (e.g., rifampin): may lower letrozole concentrations. - Selective serotonin reuptake inhibitors: monitor for additive central nervous system effects.